Skip to content

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Eli Lilly logo
Eli LillyLLY
$2.55B+290%
Pfizer logo
PfizerPFE
-$117.25M+54.2%
Amgen logo
AmgenAMGN
$571M+14.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$107.7M+150%
Gilead Sciences logo
Gilead SciencesGILD
-$67M+36.2%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s change in AP?
AnaptysBio, Inc. (ANAB) reported change in AP of -$17.82M in Q1 2026.
How has AnaptysBio, Inc.'s change in AP changed year-over-year?
AnaptysBio, Inc.'s change in AP increased by 25.9% year-over-year, from -$24.03M to -$17.82M.
What is the long-term trend for AnaptysBio, Inc.'s change in AP?
Over 3 years (2021 to 2025), AnaptysBio, Inc.'s change in AP has grown at a 164.1% compound annual growth rate (CAGR), from -$4.74M to -$87.33M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.